[go: up one dir, main page]

EP1276502A1 - Single-dose antihistamine/decongestant formulations for treating rhinitis - Google Patents

Single-dose antihistamine/decongestant formulations for treating rhinitis

Info

Publication number
EP1276502A1
EP1276502A1 EP00922278A EP00922278A EP1276502A1 EP 1276502 A1 EP1276502 A1 EP 1276502A1 EP 00922278 A EP00922278 A EP 00922278A EP 00922278 A EP00922278 A EP 00922278A EP 1276502 A1 EP1276502 A1 EP 1276502A1
Authority
EP
European Patent Office
Prior art keywords
decongestant
dosage unit
antihistamine
hours
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00922278A
Other languages
German (de)
French (fr)
Inventor
Robert E. Weinstein
Allan M. Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J-Med Pharmaceuticals Inc
Original Assignee
J-Med Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J-Med Pharmaceuticals Inc filed Critical J-Med Pharmaceuticals Inc
Publication of EP1276502A1 publication Critical patent/EP1276502A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Definitions

  • the present invention relates to treatments for rhinitis, more particularly, to combinations of decongestant and non-sedating antihistamine that avoid stimulation when stimulation is not desired.
  • Rhinitis refers to an inflammatory disorder of the nasal passages.
  • the symptoms of rhinitis typically consist of sneezing, rhinorrhea, nasal congestion, and increased nasal secretions. Failure of treatment of rhinitis may lead to other disorders that include infection of the sinuses, ears, and lower respiratory tract.
  • Two types of oral medication are commonly used to treat the symptoms of rhinitis, decongestants and antihistamines. Decongestants and antihistamines differ in their mechanisms of action, therapeutic effects, and side effects. It is common practice to combine both of these medications to bring about more complete symptom relief of rhinitis than with either entity alone.
  • Decongestants commonly used to treat rhinitis include the adrenaline-like agents pseudoephedrine and phenylpropanolamine. These agents act to constrict vessels in the nasal mucus membranes and thereby decrease tissue swelling and nasal congestion. Decongestants are found to be better than antihistamines for restoring the patency of congested nasal airways. Like adrenaline, nasal decongestants are stimulatory and produce side effects that may be tolerated while the user is awake, and may even be considered desirable to counter fatigue that is known to accompany other symptoms of rhinitis. Decongestants, however, may produce nervousness, restlessness, and insomnia if taken when sleep is desired.
  • Histamine is a mediator released from cells that line the walls of the nasal mucous membranes (mast cells). When released, histamine binds to local histamine receptors causing sneezing, nasal itching, swelling of the nasal membranes, and increased nasal secretions. Antihistamines relieve these effects, albeit by a different mechanism than decongestants. Antihistamines block the binding of histamines to the histamine receptors by preemptively binding to the receptors.
  • antihistamines are generally sedating. However, newer antihistamines with no or little sedation have been developed in the last twenty years.
  • decongestants and antihistamines utilizes both mechanistic approaches, and has been shown to offer more complete relief of rhinitis symptoms than therapy with either component alone. Consequently, many products have been formulated so that their dosage units contain both.
  • the incorporation of decongestant and sedating antihistamine into a single dosage unit attempts a balance between the stimulating and sedating side effects of these components.
  • SELDANE-D Extended-Release Tablets which contains 60 mg terfenadine (non-sedating antihistamine) and 120 mg pseudoephedrine hydrochloride (stimulating decongestant), and which is recommended to be taken every 12 hours (adults and children over 12 years of age).
  • ALLEGRA-D contains 60 mg fexofenadine (non-sedating antihistamine) and 120 mg pseudoephedrine hydrochloride (stimulating decongestant), and which is recommended to be taken every 12 hours (adults and children over 12 years of age).
  • CLARITIN-D ® 24-HOUR Extended-Release Tablets which contains 10 mg loratidine (non-sedating antihistamine) and 240 mg pseudoephedrine hydrochloride (stimulating decongestant), and which is recommended to be taken every 24 hours (adults and children over 12 years of age).
  • SYN-RXTM contains a daytime formulation of 600 mg guaifenesin, which is non-stimulating, and 60 mg pseudoephedrine, which is stimulating, and a nighttime formulation of 600 mg of guaifenesin alone.
  • SYN-RXTM does not contain an antihistamine. In failing to contain any medication that would be effective for the symptoms of rhinitis at night, SYN-RXTM does not constitute a treatment for rhinitis.
  • Another object is to formulate antihistamines and decongestants together for the treatment of rhinitis so as to avoid stimulation at night.
  • Yet another object is to provide a formulation for a user which incorporates antihistamines and decongestants together as a single dosage unit for the treatment of rhinitis in a manner so as not to cause stimulation at night and which can be taken once per day.
  • a further object is to provide a user with a single dosage unit that provides an operational combination of decongestant and antihistamine during the day and antihistamine without decongestant at night.
  • the single dosage unit of the present invention for treating the symptoms of rhinitis is expertly formulated with a combination of medications, including a nasal decongestant, antihistamine, and optionally, other medications, such as an analgesic.
  • the dosage unit is for oral ingestion.
  • the dosage unit preferably contains a non-sedating antihistamine, such as loratidine, cetirizine, or fexofenadine.
  • decongestants include pseudoephedrine and phenylpropanolamine.
  • the single dosage unit of the present invention for treating the symptoms of rhinitis contains a combination of medications that include nasal decongestants and antihistamines.
  • the dosage units may be in the form of tablets, pills, capsules, caplets, or other recognized oral form of medication.
  • the dosage unit may be formulated to contain sedating or, preferably, non-sedating antihistamine.
  • the components are formulated so as to produce the pharmacokinetic and therapeutic characteristics desired. The devising of such formulations requires pharmaceutical expertise and requires understanding of the actions, side effects, and pharmacokinetics of antihistamines, decongestants, components which affect the bioavailability of the medications, and other formulated components.
  • day and night used herein are intended to be synonymous with the period of wakefulness, when stimulation might be acceptable, and the period of sleeping, when stimulation would be undesired, respectively. Such times vary in accordance with the schedule of individuals.
  • Example 1 A single dosage unit consisting of 120 mg pseudoephedrine, a stimulating decongestant, prepared so as to be released over a 10-12 hour time, and 10 mg loratidine, a non-sedating antihistamine, formulated so as to be released immediately. When taken at the start of the day (a time anticipating a desire to be awake for 12 to 16 hours), this dosage unit provides immediate dosing with loratidine, which is known to exert an antihistaminic effect 1 to 3 hours after dosing, reach a maximum at 8 to 12 hours, and last in excess of 24 hours.
  • This dosage unit preferably provides immediate and delayed action of pseudoephedrine so as to exert an effect during daytime hours, when the stimulation of pseudoephedrine is best tolerated, but not at night.
  • pseudoephedrine has a 4 to 6 hour half-life, considerably shorter than that of loratidine.
  • the comparatively short decongestant effect of pseudoephedrine may be prolonged by release over time so as to achieve efficacy through the waking hours, but not during the time when stimulation is undesired.
  • One such time- release method involves the additional formulation of cellulose ether base materials such as hydroxypropyl methylcellulose to bond to the therapeutic agent and delay its bioavailability. Such time-release methods may be utilized to delay the bioavailability of all or only a portion of the ingested dose, and for varying lengths of time.
  • the antihistamine and decongestant components of this formulation are similar to that of CLARITIN-D ® 24-HOUR Extended-Release Tablets which contains 10 mg loratidine (antihistamine) and 240 mg pseudoephedrine hydrochloride (decongestant), and which is recommended to be taken every 24 hours in adults.
  • the present invention formulation differs, however, in that it contains a lesser dose of pseudoephedrine, and that it limits the duration of action of pseudoephedrine to the daytime hours, thus avoiding the stimulation of pseudoephedrine at night.
  • Example 2 A single dosage unit consisting of 75 mg phenylpropanolamine, a stimulating decongestant, prepared so as to be released over a 10-hour time period, and 10 mg cetirizine, a non-sedating antihistamine, prepared so as to be released immediately.
  • this formulation provides immediate dosing with cetirizine, which is known to exert an antihistaminic effect within one hour after dosing and to persist for at least 22 hours.
  • This formulation also preferably provides immediate and delayed action of phenylpropanolamine over a period not to exceed 16 hours after administration so as to exert effect during daytime hours, when stimulation is best tolerated, but exerts no effect at night.
  • Example 3 A single dosage unit consisting of 75 mg phenylpropanolamine, a stimulating decongestant prepared so as to be released over a 10-hour time period, and 120 mg of fexofenadine, a non-sedating antihistamine, prepared so as to be active over a 24-hour period.
  • Fexofenadine when given alone, exhibits antihistaminic effect within one hour, achieves a maximum effect at 12 hours, and still has a visible effect at 24 hours.
  • This formulation preferably provides immediate and delayed activity of fexofenadine over a 24-hour span.
  • This formulation also preferably provides immediate and delayed action of phenylpropanolamine over a period not in excess of 16 hours after administration so as to exert an effect during daytime hours, when stimulation is best tolerated, but not so long as to provide an effect during the time when stimulation is undesired, as at night.
  • analgesics such as salicylates and acetaminophen may be considered for inclusion in such dosage units and are within the scope of this invention.
  • analgesics such as salicylates and acetaminophen may be considered for inclusion in such dosage units and are within the scope of this invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An oral once-per-day single dosage unit for treating the symptoms of rhinitis formulated with a nasal decongestant having a duration of action of not more than about sixteen hours and antihistamine. Preferably, the antihistamine is non-sedating.

Description

SINGLE-DOSE ANTIHISTAMINE/DECONGESTANT FORMULATIONS
FOR TREATING RHINITIS
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to treatments for rhinitis, more particularly, to combinations of decongestant and non-sedating antihistamine that avoid stimulation when stimulation is not desired.
2. Description of the Prior Art
Rhinitis refers to an inflammatory disorder of the nasal passages. The symptoms of rhinitis typically consist of sneezing, rhinorrhea, nasal congestion, and increased nasal secretions. Failure of treatment of rhinitis may lead to other disorders that include infection of the sinuses, ears, and lower respiratory tract. Two types of oral medication are commonly used to treat the symptoms of rhinitis, decongestants and antihistamines. Decongestants and antihistamines differ in their mechanisms of action, therapeutic effects, and side effects. It is common practice to combine both of these medications to bring about more complete symptom relief of rhinitis than with either entity alone.
Decongestants commonly used to treat rhinitis include the adrenaline-like agents pseudoephedrine and phenylpropanolamine. These agents act to constrict vessels in the nasal mucus membranes and thereby decrease tissue swelling and nasal congestion. Decongestants are found to be better than antihistamines for restoring the patency of congested nasal airways. Like adrenaline, nasal decongestants are stimulatory and produce side effects that may be tolerated while the user is awake, and may even be considered desirable to counter fatigue that is known to accompany other symptoms of rhinitis. Decongestants, however, may produce nervousness, restlessness, and insomnia if taken when sleep is desired. This can be a source of confusion for individuals, who mistakenly attribute their inability to sleep to the malaise that may accompany other rhinitis symptoms, rather than to the decongestant medication. Histamine is a mediator released from cells that line the walls of the nasal mucous membranes (mast cells). When released, histamine binds to local histamine receptors causing sneezing, nasal itching, swelling of the nasal membranes, and increased nasal secretions. Antihistamines relieve these effects, albeit by a different mechanism than decongestants. Antihistamines block the binding of histamines to the histamine receptors by preemptively binding to the receptors. Consequently they are effective only if given prior to histamine release since once histamine is released and binds to the receptors, it is too late. Although individuals typically take antihistamines after symptoms occur, it is more desirable to dose antihistamines so as to effect therapeutic availability in anticipation of histamine release. Antihistamines are generally sedating. However, newer antihistamines with no or little sedation have been developed in the last twenty years.
Combining decongestants and antihistamines utilizes both mechanistic approaches, and has been shown to offer more complete relief of rhinitis symptoms than therapy with either component alone. Consequently, many products have been formulated so that their dosage units contain both. The incorporation of decongestant and sedating antihistamine into a single dosage unit attempts a balance between the stimulating and sedating side effects of these components.
However, individuals are known to vary in their susceptibility to these side effects. Consequently, some individuals experience stimulation and insomnia when taking these combinations at night. More recently, formulations have been commercialized which incorporate a decongestant and a non-sedating antihistamine into a single dosage unit for the purpose of avoiding daytime sedation. Such combinations might be expected to provoke a greater incidence of nighttime irritability and insomnia because the stimulating side effects of decongestant are not attenuated by concomitant sedation by antihistamine. Indeed, a 25% incidence of insomnia has been disclosed among users of a commercialized combination of the non-sedating antihistamine terfenadine and the decongestant pseudoephedrine. Examples of such formulations include:
® SELDANE-D Extended-Release Tablets which contains 60 mg terfenadine (non-sedating antihistamine) and 120 mg pseudoephedrine hydrochloride (stimulating decongestant), and which is recommended to be taken every 12 hours (adults and children over 12 years of age).
® ALLEGRA-D contains 60 mg fexofenadine (non-sedating antihistamine) and 120 mg pseudoephedrine hydrochloride (stimulating decongestant), and which is recommended to be taken every 12 hours (adults and children over 12 years of age). CLARITIN-D® 24-HOUR Extended-Release Tablets which contains 10 mg loratidine (non-sedating antihistamine) and 240 mg pseudoephedrine hydrochloride (stimulating decongestant), and which is recommended to be taken every 24 hours (adults and children over 12 years of age). These and all currently marketed single entity combinations, which are formulated with decongestant and non-sedating antihistamine, fail to address the problem of nighttime irritability and insomnia, a problem that is increased by combining non-sedating, rather than sedating antihistamine. Note is made of prior art which is directed toward reducing the side effects of antihistamines and decongestants. U.S. Patent No. 4,295,567, issued to Knudsen, teaches a regimen for employing separate day and night dosage units for the purpose of avoiding daytime sedation from sedating antihistamines. This patent does not anticipate the advent of non-sedating antihistamine and overlooks the side effect of nighttime stimulation from decongestants. A regimen, commercialized as SYN- RX™, also employs separate day and night dosage units. SYN-RX™ contains a daytime formulation of 600 mg guaifenesin, which is non-stimulating, and 60 mg pseudoephedrine, which is stimulating, and a nighttime formulation of 600 mg of guaifenesin alone. SYN-RX™ does not contain an antihistamine. In failing to contain any medication that would be effective for the symptoms of rhinitis at night, SYN-RX™ does not constitute a treatment for rhinitis. The use of multi- dosage unit regimens of such prior art is less convenient for a user than a single dose, once-per-day formulation, and more complex to follow, adding the potential for a user to confuse dosage units. Individuals with rhinitis utilize antihistamines and decongestants together many of millions of times a year. Professional as well as consumer confusion is widely encountered with the use of these medications together, and unnecessarily negative consequences occur both by self-selection and prescription. In particular, individuals treated with decongestants at night not only risk insomnia, but also daytime irritability, fatigue, and malaise from lack of rest. It is known that these side effects are sometimes mistakenly ascribed to rhinitis rather than to the medication causing them. There is a present need for formulations which circumvent this confusion and which avoid nighttime stimulation.
SUMMARY OF THE INVENTION
It is an object of the present invention to simplify the combined use of antihistamine and nasal decongestant medications for a user for the purpose of enhancing the convenience of utilizing these medications, reducing error in taking these medications, and reducing the side effects of these medications. Another object is to formulate antihistamines and decongestants together for the treatment of rhinitis so as to avoid stimulation at night. Yet another object is to provide a formulation for a user which incorporates antihistamines and decongestants together as a single dosage unit for the treatment of rhinitis in a manner so as not to cause stimulation at night and which can be taken once per day. A further object is to provide a user with a single dosage unit that provides an operational combination of decongestant and antihistamine during the day and antihistamine without decongestant at night.
The single dosage unit of the present invention for treating the symptoms of rhinitis is expertly formulated with a combination of medications, including a nasal decongestant, antihistamine, and optionally, other medications, such as an analgesic. The dosage unit is for oral ingestion. The dosage unit preferably contains a non-sedating antihistamine, such as loratidine, cetirizine, or fexofenadine. Examples of decongestants include pseudoephedrine and phenylpropanolamine. Other objects of the present invention will become apparent in light of the following detailed description of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The single dosage unit of the present invention for treating the symptoms of rhinitis contains a combination of medications that include nasal decongestants and antihistamines. The dosage units may be in the form of tablets, pills, capsules, caplets, or other recognized oral form of medication. The dosage unit may be formulated to contain sedating or, preferably, non-sedating antihistamine. The components are formulated so as to produce the pharmacokinetic and therapeutic characteristics desired. The devising of such formulations requires pharmaceutical expertise and requires understanding of the actions, side effects, and pharmacokinetics of antihistamines, decongestants, components which affect the bioavailability of the medications, and other formulated components.
The terms "day" and "night" used herein are intended to be synonymous with the period of wakefulness, when stimulation might be acceptable, and the period of sleeping, when stimulation would be undesired, respectively. Such times vary in accordance with the schedule of individuals.
Examples of the preferred single dosage units of the present invention include: Example 1. A single dosage unit consisting of 120 mg pseudoephedrine, a stimulating decongestant, prepared so as to be released over a 10-12 hour time, and 10 mg loratidine, a non-sedating antihistamine, formulated so as to be released immediately. When taken at the start of the day (a time anticipating a desire to be awake for 12 to 16 hours), this dosage unit provides immediate dosing with loratidine, which is known to exert an antihistaminic effect 1 to 3 hours after dosing, reach a maximum at 8 to 12 hours, and last in excess of 24 hours.
This dosage unit preferably provides immediate and delayed action of pseudoephedrine so as to exert an effect during daytime hours, when the stimulation of pseudoephedrine is best tolerated, but not at night. Once released, pseudoephedrine has a 4 to 6 hour half-life, considerably shorter than that of loratidine. The comparatively short decongestant effect of pseudoephedrine may be prolonged by release over time so as to achieve efficacy through the waking hours, but not during the time when stimulation is undesired. One such time- release method involves the additional formulation of cellulose ether base materials such as hydroxypropyl methylcellulose to bond to the therapeutic agent and delay its bioavailability. Such time-release methods may be utilized to delay the bioavailability of all or only a portion of the ingested dose, and for varying lengths of time.
The antihistamine and decongestant components of this formulation are similar to that of CLARITIN-D® 24-HOUR Extended-Release Tablets which contains 10 mg loratidine (antihistamine) and 240 mg pseudoephedrine hydrochloride (decongestant), and which is recommended to be taken every 24 hours in adults. The present invention formulation differs, however, in that it contains a lesser dose of pseudoephedrine, and that it limits the duration of action of pseudoephedrine to the daytime hours, thus avoiding the stimulation of pseudoephedrine at night.
Example 2. A single dosage unit consisting of 75 mg phenylpropanolamine, a stimulating decongestant, prepared so as to be released over a 10-hour time period, and 10 mg cetirizine, a non-sedating antihistamine, prepared so as to be released immediately. When taken at the start of the day, this formulation provides immediate dosing with cetirizine, which is known to exert an antihistaminic effect within one hour after dosing and to persist for at least 22 hours. This formulation also preferably provides immediate and delayed action of phenylpropanolamine over a period not to exceed 16 hours after administration so as to exert effect during daytime hours, when stimulation is best tolerated, but exerts no effect at night. Like pseudoephedrine, the comparatively short half-life and decongestant effect of phenylpropanolamine, is prolonged in this formulation by incorporating a prolonged release of phenylpropanolamine over time so as to achieve efficacy through the waking hours, but not so long as to provide phenylpropanolamine activity during the time when stimulation is undesired. Example 3. A single dosage unit consisting of 75 mg phenylpropanolamine, a stimulating decongestant prepared so as to be released over a 10-hour time period, and 120 mg of fexofenadine, a non-sedating antihistamine, prepared so as to be active over a 24-hour period. Fexofenadine, when given alone, exhibits antihistaminic effect within one hour, achieves a maximum effect at 12 hours, and still has a visible effect at 24 hours. This formulation preferably provides immediate and delayed activity of fexofenadine over a 24-hour span. This formulation also preferably provides immediate and delayed action of phenylpropanolamine over a period not in excess of 16 hours after administration so as to exert an effect during daytime hours, when stimulation is best tolerated, but not so long as to provide an effect during the time when stimulation is undesired, as at night.
In addition to antihistamines and decongestants, additional therapeutic ingredients for the treatment of rhinitis may be formulated if desired. For example, analgesics such as salicylates and acetaminophen may be considered for inclusion in such dosage units and are within the scope of this invention. These examples do not constitute an exhaustive list of potential combinations, and variations and modifications may be made by those of ordinary skill in the art. Those of skill in the art may also recognize modifications to these presently disclosed embodiments. One such modification might involve a time- release of decongestant over periods other than those exemplified, but not so as to allow stimulation at night. These variations and modifications are meant to be covered by the spirit and scope of the present claims.
Thus it has been shown and described antihistamine/decongestant formulations for treating rhinitis that satisfies the objects set forth above.
Since certain changes may be made in the present disclosure without departing from the scope of the present invention, it is intended that all matter described in the foregoing specification be interpreted as illustrative and not in a limiting sense.

Claims

What is claimed is:
1. A once-per-day single oral dosage unit comprising: a decongestant formulation having a duration of action of not more than about sixteen hours; and an antihistamine.
2. The oral dosage unit of Claim 1 wherein said decongestant is pseudoephedrine.
3. The oral dosage unit of Claim 1 wherein said decongestant is phenylpropanolamine.
4. The oral dosage unit of Claim 1 wherein said antihistamine is non-sedating.
5. The dosage unit of Claim 1 wherein the duration of action of said decongestant formulation is from about 10 hours to about 16 hours.
6. The dosage unit of Claim 5 wherein the duration of action of said decongestant formulation is about 16 hours.
7. The dosage unit of Claim 1 wherein the duration of action of said antihistamine formulation is about 24 hours.
8. The dosage unit of Claim 1 wherein said decongestant formulation is immediately released upon ingestion.
9. The dosage unit of Claim 1 wherein said decongestant formulation is time- released.
10. The dosage unit of Claim 1 wherein said antihistamine formulation is immediately released upon ingestion.
11. The dosage unit of Claim 1 wherein said antihistamine formulation is time- released.
12. A method of making a single oral dosage unit for treating rhinitis, said method comprising the steps of: formulating a quantity of decongestant to have a duration of action not more than about 16 hours in a human; formulating a quantity of antihistamine to have a duration of action greater than about 22 hours in a human; and combining said formulated quantity of decongestant and said formulated quantity of antihistamine into a single oral dosage unit.
13. The method of Claim 12 wherein said step of formulating a quantity of decongestant further includes formulating a quantity to have a duration of action of between about 12 hours to about 16 hours.
EP00922278A 2000-04-14 2000-04-14 Single-dose antihistamine/decongestant formulations for treating rhinitis Ceased EP1276502A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/010328 WO2001078782A1 (en) 2000-04-14 2000-04-14 Single-dose antihistamine/decongestant formulations for treating rhinitis

Publications (1)

Publication Number Publication Date
EP1276502A1 true EP1276502A1 (en) 2003-01-22

Family

ID=21741287

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00922278A Ceased EP1276502A1 (en) 2000-04-14 2000-04-14 Single-dose antihistamine/decongestant formulations for treating rhinitis

Country Status (5)

Country Link
EP (1) EP1276502A1 (en)
JP (1) JP5592042B2 (en)
AU (2) AU2000242484B2 (en)
CA (1) CA2405238C (en)
WO (1) WO2001078782A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0111018A (en) * 2000-05-25 2004-02-17 Schering Corp Liquid and solid stable formulations
JP2004026810A (en) * 2002-05-07 2004-01-29 Rohto Pharmaceut Co Ltd Composition for rhinitis
JP4320217B2 (en) * 2002-07-10 2009-08-26 剤盛堂薬品株式会社 Oral preparation for rhinitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
CA2268546A1 (en) * 1996-10-31 1998-05-07 Schering Corporation Composition, for the treatment of asthma, containing loratadine and a decongestant
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0178782A1 *

Also Published As

Publication number Publication date
JP5592042B2 (en) 2014-09-17
WO2001078782A1 (en) 2001-10-25
AU4248400A (en) 2001-10-30
CA2405238A1 (en) 2001-10-25
CA2405238C (en) 2014-03-18
JP2003532642A (en) 2003-11-05
AU2000242484B2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
US6051585A (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
JP5241228B2 (en) Multi-layered tablets containing non-steroidal anti-inflammatory drugs, decongestants and less sedating antihistamines
US20040031719A1 (en) Antihistamine / decongestant regimens for treating rhinitis
WO1999021556A1 (en) Antihistamine/decongestant regimens for treating rhinitis
AU2003301188B2 (en) Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
US6521254B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
US20080311196A1 (en) All Day Rhinitic Condition Treatment Regimen
AU2000242484B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
AU2000242484A1 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
JP5752578B2 (en) Single dose antihistamine / decongestant formulation for the treatment of rhinitis
US20040192781A1 (en) Method of administration for metoclopramide and pharmaceutical formulation therefor
US20080015241A1 (en) All day rhinitic condition treatment regimen
US20050192355A1 (en) Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
HK1078494B (en) Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
Davis Why use sedative antihistamines at all?: allergies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030401

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080311